Company: NIVFW
Filing Date: 2025-08-22
Form Type: DRS
Source: 0001213900-25-079717
Chunk: 39

Company: NewGenIvf Group Ltd
Filing Date: 2025-08-22
Form: DRS
Chunk 39
---
 have a material and adverse impact on NewGenIvf’s business, financial condition, and results of operations. |
| ● | Advertising or offering of gender selection services in certain jurisdictions in which NewGenIvf operates could expose NewGenIvf and its directors and executive officers to significant legal and regulatory risks, including potential penalties.                                                                                        |
| ● | Changes in NewGenIvf’s effective tax rate or tax liability may have an adverse effect on its results of operations.                                                                                                                                                                                                                        |
| ● | NewGenIvf’s reported financial results may be adversely affected by changes in accounting principles generally accepted in relevant jurisdictions.                                                                                                                                                                                         |
| ● | NewGenIvf’s reported financial results may be adversely affected by changes in accounting principles generally accepted in relevant jurisdictions.                                                                                                                                                                                         |
| ● | If NewGenIvf’s estimates or judgments relating to its critical accounting policies prove to be incorrect, its results of operations could be adversely affected.                                                                                                                                                                           |
| ● | NewGenIvf is subject to anti-corruption, anti-bribery, anti-money laundering, and similar laws, and non-compliance with such laws can subject it to criminal or civil liability and harm its business, financial condition and results of operations.                                                                                      |
| ● | NewGenIvf’s digital strategy is subject to financial, operational and regulatory risks on investing Solana.                                                                                                                                                                                                                                |
| ● | NewGenIvf’s investment in residential market of United Arab Emirates is exposed to significant market risks.                                                                                                                                                                                                                               |

<div align='center'>22</div>

Recent Development

2025 Debt Financing

On April 1, 2025, the Company
entered into a new Securities Purchase Agreement (“2025 Securities Purchase Agreement”) with certain investors named therein
(collectively, the “Buyers”), pursuant to which, amongst other things: (i) the Company agreed to sell, at an initial closing
(and such initial closing, the “Initial Closing”) a senior convertible note (the “New CB Initial Note”) in the
aggregate original principal amount not exceeding $3,200,000, convertible into Class A Ordinary Shares pursuant to its terms; and (ii)
the Company may require each Buyer (or each Buyer may require the Company, as applicable) to participate in the sale of one or more additional
convertible notes (which aggregate original principal amount for all additional convertible notes shall not exceed $25,600,000) (the “New
CB Additional Notes”).

The 2025 Securities Purchase
Agreement is filed as Exhibit